Home › Waldenstrom Macroglobulinemia › Washington › Seattle
Waldenstrom Macroglobulinemia clinical trials in Seattle, WA
5 studies for Waldenstrom Macroglobulinemia are looking for participants at sites in and around Seattle (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RecruitingPhase 1/2
- Fred Hutchinson Cancer Research Center, Seattle
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
RecruitingPhase 2
- Swedish Medical Center-First Hill, Seattle
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RecruitingPhase 1
- Swedish Cancer Institute (SCI), Seattle
Study of SGR-1505 in Mature B-Cell Neoplasms
RecruitingPhase 1
- Fred Hutchinson Cancer Center, Seattle
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
RecruitingPhase 1
- Swedish Cancer Institute, Seattle
Waldenstrom Macroglobulinemia trials in other cities
- Durham, NC10 studies
- Boston, MA9 studies
- Denver, CO7 studies
- New York City, NY6 studies
- Edison, NJ6 studies
- Dallas, TX6 studies
- Houston, TX6 studies
- Rochester, MN5 studies
- Milwaukee, WI5 studies
- Queens, NY4 studies
- Columbus, OH4 studies
- Baldwin Park, CA4 studies
Other studies in Seattle
- Non-Small Cell Lung Cancer53 studies
- Cancer (all types)49 studies
- Prostate Cancer42 studies
- Acute Myeloid Leukemia40 studies
- Breast Cancer39 studies
- Metastatic Cancer39 studies
- Colorectal Cancer34 studies
- Lung Cancer33 studies
- Ovarian Cancer30 studies
- Multiple Myeloma22 studies
- Myelodysplastic Syndromes21 studies
- Acute Lymphoblastic Leukemia21 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.